Agilent introduces fresh microarray platform to review genetic basis of developmental disorders Agilent Technologies Inc. today presented the SurePrint G3 Human being CGH+SNP microarray platform, an innovative system for simultaneous analysis of chromosomal copy number changes and copy-neutral aberrations. The system allows researchers to study the genetic basis of developmental disorders as well as many cancers. Arthur Beaudet, chairman of the Section of Human being and Molecular Genetics at Baylor College of Medication. ‘Resolution, precision and sensitivity continue at the same high amounts that researchers have come to anticipate from our CGH providing.’ The Agilent SurePrint G3 CGH+SNP arrays are available in both custom and catalog designs, similar to your current array formats.CornerStone recently began focusing on materially improving its operational functionality and plans to continue building on this success by streamlining the organization, increasing manufacturing automation, and pursuing a genuine number of growth initiatives, including adding new product capabilities and expanding distribution channels. Sunlight Capital has prior knowledge in the nutraceutical market with former affiliated portfolio organization Elan Nutrition, a formulator and producer of snack and diet bars, which doubled income and improved EBITDA from a loss to solid nearly, positive double-digit functionality during its possession by an affiliate marketer of Sun Capital Partners.